MIA PaCa-2

MIA PaCa-2 is a human pancreatic cancer cell line used extensively in pancreatic cancer research and therapy development.[1]

In 1977[2], MIA PaCa-2 cells were derived from the carcinoma of a 65-year-old male.

The cells exhibit CK5.6, AE1/AE3, E-cadherin, vimentin, chromogranin A, synaptophysin, SSTR2, and NTR1, but not CD56.[1] The cells have a round, epithelial morphology, and are adherent in cell culture.

MIA PaCa-2 has served for decades as a model of pancreatic cancer, and studies of MIA PaCa-2 physiology have helped clarify the mechanisms of carcinogenesis in pancreatic cancer[1], aid the development of cancer cell lysates targeting IgG production[3], and augmented drug-delivery methods relying on quantum dots.[4]


See also

References
  1. Gradiz, Rui; et al. (17 February 2016). "MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors". Scientific Reports. 6: 21648. Bibcode:2016NatSR...621648G. doi:10.1038/srep21648. PMC 4756684. PMID 26884312.
  2. Wu, M; et al. (3 May 1977). "Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells". Biochemistry. 16 (9): 1908–1913. doi:10.1021/bi00628a023. PMID 15590.
  3. Taniyama, Kiyomi; Kamiike, Waturu (17 February 2017). Advances in Modern Medicine. Bentham Science Publishers. pp. 117–119. ISBN 9781681080239.
  4. Devarajan, Padma V.; Jain, Sanyog (8 December 2014). Targeted Drug Delivery : Concepts and Design. Springer. pp. 596–598. ISBN 9783319113555.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.